Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia

Sun Loo; Nicola Potter; Adam Ivey; Jenny O'Nions; Roderick Moon; Jelena Jovanovic; Chun Y Fong; Natasha S Anstee; Ing Soo Tiong; Jad Othman; Chong Chyn Chua; Hanna Renshaw; Robert Baker; Shaun Fleming; Nigel H Russell; David Ritchie; Ashish Bajel; Hsin-An Hou; Richard Dillon; Andrew H Wei

doi:10.1182/blood.2024026605

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia

Blood. 2024 Dec 12;144(24):2554-2557. doi: 10.1182/blood.2024026605.

Authors

Sun Loo^{1

2

3}, Nicola Potter⁴, Adam Ivey⁵, Jenny O'Nions^{6

7}, Roderick Moon⁵, Jelena Jovanovic⁴, Chun Y Fong⁸, Natasha S Anstee^{2

3}, Ing Soo Tiong^{1

9}, Jad Othman^{4

10}, Chong Chyn Chua^{2

3

11}, Hanna Renshaw⁶, Robert Baker^{6

7}, Shaun Fleming¹², Nigel H Russell¹⁰, David Ritchie^{1

13}, Ashish Bajel^{1

13}, Hsin-An Hou¹⁴, Richard Dillon^{4

10}, Andrew H Wei^{1

2

3}

Affiliations

¹ Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia.
² The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
³ Department of Medical Biology, University of Melbourne, Melbourne, Australia.
⁴ Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.
⁵ Molecular Pathology, The Alfred Hospital, Melbourne, Australia.
⁶ Department of Haematology, University College London NHS Foundation Trust, London, United Kingdom.
⁷ Specialist Integrated Haematology Malignancy Diagnostic Service, Health Services Laboratories, University College London Hospitals NHS Foundation Trust, University College London, London, United Kingdom.
⁸ Department of Haematology, Austin Hospital, Melbourne, Australia.
⁹ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
¹⁰ Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
¹¹ Department of Haematology, Monash Health, Clayton, Australia.
¹² Department of Haematology, The Alfred Hospital and Monash University, Melbourne, Australia.
¹³ Department of Medicine, University of Melbourne, Melbourne, Australia.
¹⁴ Division of Hematology and Division of General Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.

PMID: 39316646
DOI: 10.1182/blood.2024026605

Abstract

Pretransplant detection of KMT2Ar measurable residual disease ≥0.001% by quantitative polymerase chain reaction was associated with significantly inferior posttransplant survival (2-year relapse-free survival 17% vs 59%; P = .001) and increased 2-year cumulative incidence of relapse (75% vs 25%, P = .0004).

MeSH terms

Adolescent
Adult
Aged
Female
Gene Rearrangement
Hematopoietic Stem Cell Transplantation
Histone-Lysine N-Methyltransferase* / genetics
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / mortality
Male
Middle Aged
Myeloid-Lymphoid Leukemia Protein* / genetics
Neoplasm, Residual* / diagnosis
Neoplasm, Residual* / genetics
Oncogene Proteins, Fusion / genetics
Prognosis
Young Adult

Substances

Myeloid-Lymphoid Leukemia Protein
KMT2A protein, human
Histone-Lysine N-Methyltransferase
Oncogene Proteins, Fusion